Tussey
Christopher Brian Tussey, Lexington, NC US
Patent application number | Description | Published |
---|---|---|
20110139307 | DISTRESSING PROCESS AND APPARATUS FOR APPLYING SUCH PROCESS - A method is provided for treating the decorative face of a panel to simulate the visual effect of a distressed panel. The decorative face may include at least a layer of wood or the like. The method may involve passing the panel with respect to two or more distressing tools. The passing may be performed in an automated way by first driving means. The method may also involve advancing the distressing tools intermittently toward the moving panel to apply distress marks. The intermittently advancing may be performed in an automated way by second, third and optional further driving means. At least one of the passing of the panel and the advancing of the distressing tools toward the moving panel may be performed according to an irregular rhythm in order to obtain irregularly spaced distress marks. At least one of the first driving means, the second driving means, the third driving means, and the optional further driving means is steered by and therefore coupled to program means. | 06-16-2011 |
James Mitchell Tussey, Caro, MI US
Patent application number | Description | Published |
---|---|---|
20130238352 | Stream-lined system for electronically recording doctor-written prescriptions coupled with paper and electronic viewing methods, tailored for retail pharmacy operations - A pharmacy process for effecting the capture and storage of an electronic image of a paper-prescription written by a doctor that minimizes human effort, cost, and occupied space while filling the prescription. Use is made of only one computer-with-memory-and-a-computer-program, one computer-controllable specialized-scanner, one strip-printer, at least one computer-controlled conventional-printer to print peel-off labels or a Clinical Label, and such number of simple terminals as are needed for the workload of the pharmacy. Each simple terminal has a monitor, keyboard, and bar-code scanner. Whether a first filling or a refilling, the critical and necessary procedure of a Pharmacist's review-verification of the filled vials (and their labels) being in full compliance with the prescribing doctor's requirements is facilitated by providing a legible-image of the original prescription on a monitor even if the prescription's paper is copy-resistant. | 09-12-2013 |
Jim M. Tussey, Caro, MI US
Patent application number | Description | Published |
---|---|---|
20080197619 | Pharmacy Printer Blank Sheet And Method For Avoiding Printer Misfeeds - A two section pharmacy printer blank sheet for printing information text and labels for drug prescription drugs when dispensing prescription drugs and a method which reduces printer misfeeds in U feed printers to allow use of the simpler, more reliable U-feed printers to be successfully used for on site printing of the pharmacy printer blanks. The lower side of one of the labels is spaced closer to overlapped strip parts of the printer blank sections to reduce the tendency for one of the section edges to catch a lower side edge of the labels in a U-feed printer to minimize printer misfeeds. | 08-21-2008 |
Lynda Tussey, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20130095130 | Methods and Compositions for Providing Protective Immunity in the Elderly - Compositions that include a flagellin/antigen protein comprising at least a portion of at least one flagellin and at least a portion of at least one antigen and methods of administering these compositions to humans at least 49 years old. The compositions stimulate immune response to the antigen, in particular, a protective immune response to the antigen, in the human, such as an elderly human. | 04-18-2013 |
20140205624 | TETRAVALENT AND MIXED HEAD BIVALENT DENGUE VACCINE - The present invention relates to immunogenic compositions and vaccines of flavivirus. In particular, the present invention relates to improved Dengue vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine. The vaccines and immunogenic compositions of the present invention relate to mixed head bivalent flagellin-dengue antigen fusion proteins which can be combined with other bivalent dengue antigen fusion proteins or monovalent dengue antigen fusion proteins to produce multivalent vaccine including tetravalent vaccines. | 07-24-2014 |
Lynda Tussey, Cranbury, NJ US
Patent application number | Description | Published |
---|---|---|
20130330367 | COMPOSITIONS WITH ENHANCED IMMUNOGENICITY AND/OR REDUCED REACTOGENICITY - The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity. The present invention also relates to methods of evaluating the vaccines by measuring the relative expression of certain gene markers. Altered expression of the genes relative to flagellin control sample may indicate that the vaccine is suitable to stimulate an adaptive immune response to the antigen component in the subject with minimal side effects. | 12-12-2013 |
20140065177 | FUSION PROTEINS AND METHODS OF USE - Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin. | 03-06-2014 |
20140235836 | Immunologic Constructs and Methods - The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity and/or improve folding of the protein. | 08-21-2014 |
20140255438 | FUSION PROTEINS AND METHODS OF USE - Compositions that include a fusion protein comprising flagellin and at least one antigen that has an isoelectric point greater than about 7.0 and that is fused to at least one domain 3 of the flagellin activate Toll-like Receptor 5. Methods of stimulating an immune response, in particular, a protective immune response include administering a composition that includes an antigen fused to a loop of domain 3 of flagellin. | 09-11-2014 |
Lynda G. Tussey, Cranbury, NJ US
Patent application number | Description | Published |
---|---|---|
20130136763 | Methods Of Treatment With Compositions That Include Hemagglutinin - Methods that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. Compositions administered to the subject can further include a carrier and can be administered in single or multiple doses. | 05-30-2013 |
20130224798 | Methods of Making Hemagglutinin Proteins - Methods of making a protein that stimulates a protective immune response in a subject include separating a portion of a protein from a naturally occurring influenza viral hemagglutinin to form a protein portion. The protein portion includes at least a portion of a globular head, and at least a portion of at least one secondary structure having at least one β-sheet at a bottom of the globular head that causes the globular head to essentially retain its tertiary structure. The protein portion made by the methods of the invention lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. A nucleic acid sequence encoding the protein portion is transformed into a prokaryotic host cell. | 08-29-2013 |
Lynda G. Tussey, Princeton, NJ US
Patent application number | Description | Published |
---|---|---|
20110135680 | DELETION MUTANTS OF FLAGELLIN AND METHODS OF USE - Compositions that include Toll-like Receptor 5 agonists and at least a portion of at least one viral antigen can be employed in methods that stimulate an immune response in a subject, in particular, a protective immune response in a subject. Compositions can be associated with particles and employed in the methods in relatively low doses to provide protective immunity to viral infection. | 06-09-2011 |
20140050749 | MHC-I Restricted Epitopes Containing Non-Natural Amino Acid Residues - The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus. The exemplary polypeptides are derived from the survivin, hTERT, CYP1B1 and MART-1 antigens. | 02-20-2014 |